A Prospective Study to Evaluate the Role of Complexed Prostate Specific Antigen and Free/Total Prostate Specific Antigen Ratio for the Diagnosis of Prostate Cancer

Mitchell, I.V.; Croal, Bernard; Dickie, A.; Cohen, Nicholas; Ross, Iain

doi:10.1097/00005392-200105000-00033

Cited by 13 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, nonmalignant prostatic diseases, especially benign prostatic hyperplasia (BPH) and acute prostatitis, also cause serum PSA elevation, thus complicating the diagnosis of prostatic cancer by PSA measurements alone (Polascik et al, 1999). The evaluation of the molecular forms of PSA improves the specificity of PSA (Mitchell et al, 2001;Stephan et al, 2002). Despite the availability of these tests, there is an urgent need for new biomarkers for early detection of prostate cancer.…”

mentioning

confidence: 99%

Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues

et al. 2003

View full text Add to dashboard Cite

Macrophage inhibitory cytokine-1 (MIC-1) gene is a member of transforming growth factor-b superfamily and was reported to be highly overexpressed in human prostate cancer using microarray technology. The aim of this study was to evaluate the quantitative expression of MIC-1 in malignant and benign prostate tissues and to associate expression levels with clinicopathological parameters of prostate cancer. Matched (paired) prostatic tissue samples from the cancerous and noncancerous parts of the same prostates were obtained from 66 patients who underwent radical prostatectomy. Quantitative RT -PCR was performed using SYBR Green I on the Roche LightCycler TM system. Macrophage inhibitory cytokine-1 gene overexpression in cancerous tissues was observed in 88% of cases, compared to noncancerous tissues (Po0.001). The expression level of MIC-1 in cancerous tissues was significantly higher than in noncancerous tissue (Po0.001). Higher expression of MIC-1 gene was significantly associated with higher Gleason score (P ¼ 0.004). The expression of the MIC-1 gene in prostate cancer is significantly higher than in noncancerous tissues, especially in more aggressive forms of the disease (Gleason score45). This is in contrast to prostate-specific antigen that is downregulated in higher-grade tumours. The upregulation of MIC-1 in prostate cancer and in advanced and more aggressive prostatic tumours suggests that MIC-1 protein should be evaluated as a potential diagnostic and prognostic biomarker.

show abstract

mentioning

confidence: 99%

Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues

et al. 2003

View full text Add to dashboard Cite

show abstract

“…[18][19][20][21][22] When PCa patients compared with healthy people, sensitivity and specificity values of serum PSA levels are about 75% and 55%, respectively. Many of the patients subjected to a biopsy procedure after a screening test received BPH rather than a PCa diagnosis and people were faced complications and costs of unnecessary biopsies.…”

Section: Discussionmentioning

confidence: 99%

Neutrophil gelatinase- associated lipocalin as a screening test in prostate cancer

Muşlu

Ercan

Akbayir³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: Prostate specific antigen (PSA) with digital rectal examination is used for diagnosis of prostate cancer (PCa), where definite diagnosis can only be made by prostate biopsy. Recently neutrophil gelatinaseassociated lipocalin (NGAL), a lipocalin family member glycoprotein, come into prominence as a cancer biomarker. This study is aimed to test serum NGAL as a diagnostic biomarker for PCa and discriminate PCa from benign prostatic hyperplasia (BPH). Material and methods:In this prospective study, 90 patients who underwent transrectal ultrasound-guided 12-core prostate biopsy between May 2015 and September 2015, were evaluated. Histopathologically diagnosed 45 PCa and 45 BPH patients were enrolled in this study. Serum NGAL and PSA levels of all participants were measured, then these data were evaluated by statistical programs. Results: When sensitivity fixed to 80% specificity of NGAL was better than PSA (49%, 31% respectively). Receiver operating characteristic (ROC) curve analysis showed that NGAL alone or its combined use with PSA have better area under curve (AUC) results than PSA alone (0.662, 0.693, and 0.623 respectively). Conclusion: In conclusion NGAL gave promising results such as increased sensitivity and a better AUC values in order to distinguish PCa from BPH. NGAL showed a potential to be a non-invasive biomarker which may decrease the number of unnecessary biopsies.

show abstract

“…In studies with an overrepresentation of patients with BPH at lower PSA levels and patients with prostate cancer at higher PSA levels, cPSA enhanced the specificity of tPSA to levels equal or even better than that of %fPSA. 16,17 However, other studies using more equal tPSA distributions in patients with BPH and prostate cancer could only show a slightly better diagnostic performance of cPSA alone compared with tPSA. 36,38,39 Only the cPSA/tPSA ratio could reach specificity levels comparable to %fPSA.…”

Section: Psa-act and Cpsamentioning

confidence: 96%

“…The Bayer cPSA assay measures both PSA-ACT and PSA-API and has been proposed as a single assay, as an alternative to the fPSA and tPSA assays. 16,17 Other existing PSA complexes are so far not measurable in serum. 18 fPSA has recently been shown to exist in three molecular forms; proPSA, 19 BPSA, 20 a special clipped form of fPSA, and inactive "intact" PSA (fPSA-I).…”

Section: Molecular Forms Of Psa (Hk3)mentioning

confidence: 99%

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

Stephan

Jung

Diamandis

et al. 2002

Urology

View full text Add to dashboard Cite

A Prospective Study to Evaluate the Role of Complexed Prostate Specific Antigen and Free/Total Prostate Specific Antigen Ratio for the Diagnosis of Prostate Cancer

Abstract: Our study revealed that the overall diagnostic performance of Bayer complexed PSA appears to be better than the other PSA tests and ratios studied. The use of Bayer complexed PSA may lead to a reduction in the number of men undergoing unnecessary prostatic biopsy.

Cited by 13 publications

References 16 publications

Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues

Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues

Neutrophil gelatinase- associated lipocalin as a screening test in prostate cancer

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

Contact Info

Product

Resources

About